Evan Seigerman's Stock Ratings

BMO Capital Analyst

Evan Seigerman is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

8.40%

Smart Score

64.8%

Overall Average Return Percentile

58th

Number of Ratings

60
Buy NowGet Alert
07/03/2024LLYBuy Now
Eli Lilly and Co
$920.008.8%$1001 → $1001MaintainsOutperformGet Alert
07/02/2024INCYBuy Now
Incyte
$58.17-17.48%$52 → $48DowngradeMarket Perform → UnderperformGet Alert
06/17/2024IRONBuy Now
Disc Medicine
$47.5047.37%$50 → $70ReiteratesOutperform → OutperformGet Alert
05/31/2024VRTXBuy Now
Vertex Pharmaceuticals
$481.893.76%$480 → $500MaintainsOutperformGet Alert
05/02/2024NBIXBuy Now
Neurocrine Biosciences
$142.24-2.98%$129 → $138MaintainsMarket PerformGet Alert
05/01/2024LLYBuy Now
Eli Lilly and Co
$920.008.8%$900 → $1001MaintainsOutperformGet Alert
05/01/2024INCYBuy Now
Incyte
$58.17-10.61%$56 → $52MaintainsMarket PerformGet Alert
04/26/2024BMYBuy Now
Bristol-Myers Squibb
$39.9020.3%$55 → $48MaintainsMarket PerformGet Alert
04/02/2024IRONBuy Now
Disc Medicine
$47.505.26%—MaintainsOutperformGet Alert
02/29/2024IRONBuy Now
Disc Medicine
$47.5068.42%$70 → $80MaintainsOutperformGet Alert
02/14/2024BIIBBuy Now
Biogen
$228.0724.96%$295 → $285MaintainsOutperformGet Alert
02/14/2024INCYBuy Now
Incyte
$58.1710.02%$58 → $64MaintainsMarket PerformGet Alert
02/07/2024LLYBuy Now
Eli Lilly
$920.00-5.98%$710 → $865MaintainsOutperformGet Alert
11/10/2023NBIXBuy Now
Neurocrine Biosciences
$142.24-29.7%$111 → $100MaintainsMarket PerformGet Alert
11/09/2023BIIBBuy Now
Biogen
$228.0729.35%$314 → $295MaintainsOutperformGet Alert
11/07/2023VRTXBuy Now
Vertex Pharmaceuticals
$481.89-13.88%$389 → $415MaintainsOutperformGet Alert
10/27/2023BMYBuy Now
Bristol-Myers Squibb
$39.9050.38% → $60DowngradeOutperform → Market PerformGet Alert
09/13/2023NBIXBuy Now
Neurocrine Biosciences
$142.24-21.96%$100 → $111MaintainsMarket PerformGet Alert
08/09/2023LLYBuy Now
Eli Lilly
$920.00-31.2%$565 → $633MaintainsOutperformGet Alert
08/08/2023BIIBBuy Now
Biogen
$228.0747.32%$347 → $336MaintainsOutperformGet Alert
08/02/2023INCYBuy Now
Incyte
$58.1716.9%$70 → $68MaintainsMarket PerformGet Alert
08/02/2023VRTXBuy Now
Vertex Pharmaceuticals
$481.89-19.28%$385 → $389MaintainsOutperformGet Alert
08/02/2023NBIXBuy Now
Neurocrine Biosciences
$142.24-29.7%$96 → $100MaintainsMarket PerformGet Alert
07/28/2023BMYBuy Now
Bristol-Myers Squibb
$39.9097.99%$87 → $79MaintainsOutperformGet Alert
07/26/2023BIIBBuy Now
Biogen
$228.0752.15%$357 → $347MaintainsOutperformGet Alert
07/06/2023NBIXBuy Now
Neurocrine Biosciences
$142.24-32.51%$91 → $96UpgradeUnderperform → Market PerformGet Alert
06/12/2023IRONBuy Now
Disc Medicine
$47.5047.37%$40 → $70MaintainsOutperformGet Alert
05/16/2023GILDBuy Now
Gilead Sciences
$67.7147.68%$90 → $100UpgradeMarket Perform → OutperformGet Alert
05/04/2023LLYBuy Now
Eli Lilly
$920.00-45.11%$430 → $505MaintainsOutperformGet Alert
05/03/2023INCYBuy Now
Incyte
$58.1720.34%$75 → $70MaintainsMarket PerformGet Alert
05/02/2023VRTXBuy Now
Vertex Pharmaceuticals
$481.89-20.11% → $385MaintainsOutperformGet Alert
03/23/2023IRONBuy Now
Disc Medicine
$47.50-15.79% → $40Initiates → OutperformGet Alert
02/28/2023GPCRBuy Now
Structure Therapeutics
$37.237.44% → $40Initiates → OutperformGet Alert
02/08/2023VRTXBuy Now
Vertex Pharmaceuticals
$481.89-26.33% → $355MaintainsOutperformGet Alert
12/08/2022MRTXBuy Now
Mirati Therapeutics
——$110 → $59DowngradeOutperform → Market PerformGet Alert
10/14/2022REPLBuy Now
Replimune Group
$8.44373.93%$30 → $40MaintainsOutperformGet Alert
09/28/2022BIIBBuy Now
Biogen
$228.0757.85%$217 → $360UpgradeMarket Perform → OutperformGet Alert
09/12/2022BMYBuy Now
Bristol-Myers Squibb
$39.90135.59%$92 → $94MaintainsOutperformGet Alert
08/04/2022REGNBuy Now
Regeneron Pharmaceuticals
$1.05K-25.11%$757 → $788MaintainsOutperformGet Alert
08/02/2022NUVBBuy Now
Nuvation Bio
$3.16-20.89%$8 → $2.5DowngradeOutperform → Market PerformGet Alert
05/02/2022BMYBuy Now
Bristol-Myers Squibb
$39.90130.58%$87 → $92MaintainsOutperformGet Alert
04/29/2022GILDBuy Now
Gilead Sciences
$67.71-6.96%$65 → $63MaintainsMarket PerformGet Alert
04/29/2022LLYBuy Now
Eli Lilly
$920.00-61.09%$330 → $358MaintainsOutperformGet Alert
04/28/2022AMGNBuy Now
Amgen
$311.46-21.98%$263 → $243MaintainsMarket PerformGet Alert
03/31/2022CADLBuy Now
Candel Therapeutics
$5.97100.9%$18 → $12MaintainsOutperformGet Alert
03/30/2022BMYBuy Now
Bristol-Myers Squibb
$39.90103.01%$74 → $81MaintainsOutperformGet Alert
03/22/2022NUVBBuy Now
Nuvation Bio
$3.16279.75%$17 → $12MaintainsOutperformGet Alert
02/28/2022GILDBuy Now
Gilead Sciences
$67.71-4.01%$75 → $65DowngradeOutperform → Market PerformGet Alert
02/04/2022BIIBBuy Now
Biogen
$228.074.35%$260 → $238DowngradeOutperform → Market PerformGet Alert
01/20/2022VRTXBuy Now
Vertex Pharmaceuticals
$481.89-43.14%$202 → $274UpgradeMarket Perform → OutperformGet Alert
11/19/2021MRTXBuy Now
Mirati Therapeutics
———Initiates → OutperformGet Alert
11/19/2021PFEBuy Now
Pfizer
$27.94114.75%—Initiates → OutperformGet Alert
11/19/2021BMYBuy Now
Bristol-Myers Squibb
$39.9080.45%—Initiates → OutperformGet Alert
11/19/2021LLYBuy Now
Eli Lilly
$920.00-66.2%—Initiates → OutperformGet Alert
11/19/2021INCYBuy Now
Incyte
$58.1728.93%—Initiates → Market PerformGet Alert
11/19/2021BIIBBuy Now
Biogen
$228.0738.12%—Initiates → OutperformGet Alert
11/19/2021AMGNBuy Now
Amgen
$311.46-26.8%—Initiates → Market PerformGet Alert
11/19/2021NBIXBuy Now
Neurocrine Biosciences
$142.24-46.57%—Initiates → UnderperformGet Alert
11/19/2021VRTXBuy Now
Vertex Pharmaceuticals
$481.89-58.08%—Initiates → Market PerformGet Alert
04/21/2020VRTXBuy Now
Vertex Pharmaceuticals
$481.89-38.16%$258 → $298MaintainsOutperformGet Alert